During Thursday’s current trade, Curis, Inc. (NASDAQ:CRIS)’s shares decline -1.32% to $2.98.
Curis, Inc. (CRIS) declared results from the accomplished dose escalation and ongoing expansion stages of a Phase 1 trial of CUDC-907, an oral dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes. Data were presented at the Annual Meeting of American Society of Clinical Oncology (ASCO) that is being held in Chicago, IL. At the recommended Phase 2 dose and plan, CUDC-907 has demonstrated evidence of clinical activity with objective responses observed in patients with relapsed/ refractory diffuse large B cell lymphoma (DLBCL) and Hodgkin’s lymphoma (HL). Two complete responses (CRs) and 4 partial responses (PRs) were stated in 10 response evaluable patients with DLBCL, counting 3 responses (1 CR and 2 PRs) in patients with transformed follicular lymphoma (t-FL/DLBCL), a very difficult to treat subset of DLBCL. One patient with HL practiced partial response out of a total of 12 response evaluable patients with HL. In addition, stable disease (SD) has been observed in 25 of 44 response evaluable patients across various lymphomas and multiple myeloma (MM).
The Phase 1 dose escalation and expansion study was designed to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose, in addition to preliminary anti-cancer activity of oral CUDC-907 in patients with relapsed/ refractory lymphoma or MM. As of the April 27, 2015 data cut-off for the ASCO presentation, a total of 57 patients had been enrolled in the study, with 40 and 17 patients in the dose escalation and expansion phases of the study, respectively. In the accomplished dose escalation phase, patients either received CUDC-907 daily (QD, doses: 30 or 60 mg), or intermittently on twice weekly (BIW) or thrice weekly (TIW) plans (daily doses: 60, 90, 120 or 150 mg), or on a 5 days on, 2 days off (5/2) plan (dose:60 mg). In the ongoing expansion phase, patients either receive CUDC-907 60 mg on the 5/2 plan or 120 mg on the TIW plan.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma.
Sorrento Therapeutics Inc (NASDAQ:SRNE)‘s shares gain 3.69% to $17.41, during the current trading session Thursday’s, hitting its highest level.
Advaxis, Inc. (ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has reached a non-exclusive research and clinical trial partnershipagreement with Sorrento Therapeutics, Inc. (SRNE) to evaluate combinations of Advaxis’s Lm-LLO cancer immunotherapy technology platform, counting ADXS-HPV, ADXS-PSA and ADXS-HER2, with Sorrento’s fully human antibodies targeting immune checkpoints, counting GITR, OX40, LAG-3 and TIM-3. Sorrento has one of the largest and most diverse fully human antibody libraries in the industry designed to facilitate rapid identification and selection of highly specific therapeutic monoclonal antibody (mAb) product candidates.
Advaxis’s preclinical program for ADXS-HPV formerly examined its therapeutic potential in combination with agonistic research antibodies, counting anti-OX40 and anti-GITR. Preclinical data demonstrated that the combination of ADXS-HPV with agonistic research antibodies led to noteworthy inhibition of tumor growth and prolonged survival in tumor-bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively (AACR Abstract #LB-229).
Sorrento Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. The company primary therapeutic focus is oncology, counting the treatment of chronic cancer pain, in addition to developing therapeutic products for other indications, such as immunology and infectious diseases.
In a afternoon trade, Herman Miller, Inc. (NASDAQ:MLHR)‘s shares surge 2.13% to $30.62.
Herman Miller Inc. (MLHR) declared results for its fourth quarter and fiscal year ended May 30, 2015. Net sales in the quarter totaled $550.7 million, an increase of 13.0% from the same quarter last fiscal year. New orders in the fourth quarter of $556.9 million were 16.1% above the prior year level.
On an organic basis, which adjusts for acquisitions, divestitures, and foreign currency translation, sales in the fourth quarter increased 3.9% from the same quarter last fiscal year.
Herman Miller reported diluted earnings per share of $0.39 in the fourth quarter. This compares to diluted earnings per share of $0.28 in the same quarter last fiscal year. Excluding the impact of an asset impairment charge and a one-time tax benefit, adjusted diluted earnings per share in the fourth quarter totaled $0.47. The translation impact from year-over-year changes in currency exchange rates had an unfavorable impact on earnings per share of approximately $0.05 in the quarter. In the fourth quarter of last fiscal year, the company reported adjusted diluted earnings per share of $0.50.
Herman Miller, Inc. is engaged in the research, design, manufacture, and distribution of office furniture systems, seating products, other freestanding furniture elements, textiles, and related services in the United States and internationally. It provides modular systems under the Canvas Office Landscape, Locale, Metaform Portfolio, Public Office Landscape, Action Office, Ethospace, Resolve, and My Studio Environments; seating products under the Embody, Aeron, Mirra, Mirra2, Setu, Sayl, Celle, Equa, and Ergon; and storage products under the Meridian and Tu names.
Healthways, Inc. (NASDAQ:HWAY), during its Thursday’s current trading session 0.16% loss and closed at $12.32.
Global well-being improvement leader Healthways, Inc. (HWAY) and world-leading administration consulting firm Gallup have released their comprehensive analysis of well-being around the world, the Gallup-Healthways State of Global Well-Being: 2014 Country Well-Being Rankings Report. According to the report, Panama was the nation with the highest well-being for the second year in a row, while Afghanistan was the nation with the lowest overall well-being. The United States ranked 23rd in the 2014 global rankings, down from 12th in 2013.
The analysis is based on data from the Gallup-Healthways Global Well-Being Index, a definitive measure and empiric database of real-time changes in well-being throughout the world. More than 146,000 interviews in 145 countries fueled the 2014 analysis, which serves as a global barometer of individuals’ perceptions of their well-being across five elements: purpose, social, financial, community and physical. The Global Well-Being Index captures important aspects of how people feel about and experience their daily lives, counting topics that span how much they like what they do, their social relationships, their financial security and their relationship to their community, as well as their physical health.
The Americas have the highest percentages thriving in three or more elements and lead other regions in their purpose, social, community and physical well-being. Latin Americans in particular have higher levels of well-being than any other regional group. European countries dominated in financial well-being, representing nine of the top ten countries. Globally, overall well-being remained unchanged from 2013, with only 17 percent of residents in the 145 countries surveyed thriving in three or more elements.
Healthways, Inc., together with its auxiliaries, provides population health administration solutions to assist people to enhance well-being and health. The company provides personalized solutions for individuals, irrespective of their health status, age, or paying sponsor.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
